Skip to content
Preprint · CC-BY via OpenAlex

A drug cocktail of rapamycin, acarbose, and phenylbutyrate enhances resilience to features of early-stage Alzheimer’s disease in aging mice

Jackson Wezeman, Martin Darvas, Nadia Postupna, Jenna Klug, Ruby Mangalindan, Addison Keely, Kathryn Nguyen, Chloe Johnson, Manuela Rosenfeld, Warren Ladiges

bioRxiv (Cold Spring Harbor Laboratory) · 2024 · ▲ 2 citations

Abstract

The process of aging is defined by the breakdown of critical maintenance pathways leading to an accumulation of damage and its associated phenotypes. Aging affects many systems and is considered the greatest risk factor for a number of diseases. Therefore, interventions aimed at establishing resilience to aging should delay or prevent the onset of age-related diseases. Recent studies have shown a three-drug cocktail consisting of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition), acarbose, and phenylbutyrate delayed the onset of physical, cognitive, and biological aging phenotypes in old mice. To test the ability of this drug cocktail to impact Alzheimer's disease (AD), an adeno-associated-viral vector model of AD was created. Mice were fed the drug cocktail 2 months prior to injection and allowed 3 months for phenotypic development. Cognitive phenotypes were evaluated through a spatial navigation learning task. To quantify neuropathology, immunohistochemistry was performed for AD proteins and pathways of aging. Results suggested the drug cocktail was able to increase resilience to cognitive impairment, inflammation, and AD protein aggregation while enhancing autophagy(definition) and synaptic integrity, preferentially in female cohorts. In conclusion, female mice were more susceptible to the development of early stage AD neuropathology and learning impairment, and more responsive to treatment with the drug cocktail in comparison to male mice. Translationally, a model of AD where females are more susceptible would have greater value as women have a greater burden and incidence of disease compared to men. These findings validate past results and provide the rationale for further investigations into enhancing resilience to early-stage AD by enhancing resilience to aging.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1101/2024.01.26.577437
Canonical
link ↗
Fetched
2026-06-29 MST

Cite this

APA
Wezeman, J., Darvas, M., Postupna, N., Klug, J., Mangalindan, R., Keely, A., Nguyen, K., Johnson, C., Rosenfeld, M., &amp; Ladiges, W. (2024). A drug cocktail of rapamycin, acarbose, and phenylbutyrate enhances resilience to features of early-stage Alzheimer’s disease in aging mice. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.1101/2024.01.26.577437
Vancouver
Wezeman J, Darvas M, Postupna N, Klug J, Mangalindan R, Keely A, et al. A drug cocktail of rapamycin, acarbose, and phenylbutyrate enhances resilience to features of early-stage Alzheimer’s disease in aging mice. bioRxiv (Cold Spring Harbor Laboratory). 2024. doi:10.1101/2024.01.26.577437.
BibTeX
@unpublished{jackson2024Adrugc, title = {A drug cocktail of rapamycin, acarbose, and phenylbutyrate enhances resilience to features of early-stage Alzheimer’s disease in aging mice}, author = {Jackson Wezeman and Martin Darvas and Nadia Postupna and Jenna Klug and Ruby Mangalindan and Addison Keely and Kathryn Nguyen and Chloe Johnson and Manuela Rosenfeld and Warren Ladiges}, journal = {bioRxiv (Cold Spring Harbor Laboratory)}, year = {2024}, doi = {10.1101/2024.01.26.577437}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings